Sotera Health Company (NASDAQ:SHC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Sotera Health Company has received a consensus rating of "Moderate Buy" from five analysts, with one hold and four buy recommendations.
• The average 12-month price target for Sotera Health is $16.00, with Goldman Sachs recently raising their target to $17.00 while Barclays lowered theirs to $13.00.
• Institutional investors own 91.03% of Sotera Health's stock, with significant stake acquisitions reported from multiple investment firms in recent quarters.

Sotera Health Company (NASDAQ:SHC - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $16.00.

A number of equities analysts have weighed in on SHC shares. Barclays decreased their target price on Sotera Health from $15.00 to $13.00 and set an "overweight" rating for the company in a research report on Tuesday, June 24th. Piper Sandler reduced their price target on shares of Sotera Health from $15.00 to $13.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Wall Street Zen raised shares of Sotera Health from a "hold" rating to a "buy" rating in a research report on Saturday, June 28th. Finally, The Goldman Sachs Group raised shares of Sotera Health from a "neutral" rating to a "buy" rating and upped their price target for the company from $14.00 to $17.00 in a research report on Monday, May 5th.

Institutional Trading of Sotera Health

Institutional investors have recently made changes to their positions in the company. TPG GP A LLC acquired a new position in Sotera Health during the first quarter worth $79,126,000. Sculptor Capital LP acquired a new position in Sotera Health during the fourth quarter worth $68,400,000. Two Seas Capital LP boosted its stake in Sotera Health by 624.0% during the fourth quarter. Two Seas Capital LP now owns 2,896,136 shares of the company's stock worth $39,619,000 after buying an additional 2,496,136 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its stake in Sotera Health by 140.8% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 2,624,750 shares of the company's stock worth $35,907,000 after buying an additional 1,534,666 shares during the last quarter. Finally, Ananym Capital Management LP purchased a new stake in Sotera Health in the fourth quarter valued at $13,680,000. 91.03% of the stock is owned by institutional investors and hedge funds.

Sotera Health Price Performance

SHC traded down $0.23 on Friday, reaching $11.91. The company had a trading volume of 884,647 shares, compared to its average volume of 914,026. The business has a 50 day simple moving average of $11.72 and a 200 day simple moving average of $12.10. The company has a market cap of $3.38 billion, a price-to-earnings ratio of 148.89 and a beta of 1.81. The company has a debt-to-equity ratio of 5.55, a quick ratio of 2.19 and a current ratio of 2.46. Sotera Health has a 52-week low of $9.53 and a 52-week high of $17.08.

Sotera Health (NASDAQ:SHC - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.02. Sotera Health had a net margin of 2.24% and a return on equity of 41.08%. The firm had revenue of $254.52 million for the quarter, compared to analysts' expectations of $245.56 million. During the same quarter last year, the business earned $0.13 earnings per share. The business's revenue was up 2.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Sotera Health will post 0.61 EPS for the current year.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.